For this year, Gilead Sciences Inc. (NASDAQ:GILD). From Morgan Stanley analyst Matthew Harrison’s perspective, the revised guidelines indicate potential to garner $200 million for the biotech giant. The Stock now has a Weekly Volatility of 1.40% and Monthly Volatility of 1.48%.
Advertisement
However, while certainly welcome news, Harrison remains cautiously optimistic as he deems this will most likely bring about a “minimal direct impact to GILD”, given that all patients in Colorado would need to be treated for the firm to attain the full $200 million in additional revenue. According to these analysts, the Low Revenue Estimate for Gilead Sciences, Inc.is 7.22 Billion and the High Revenue Estimate is 7.98 Billion. The consensus rating is 2.5, suggesting the market has given up on the stock. However its lowest revenue estimates are $7.22B and highest revenue estimates are $7.99B. The share price of the stock plunged -28.5% for the year.
Gilead Sciences Inc.’s (GILD) witnessed a gain of 1.29% in recent trading period with closing price of $ 77.88. Also, the Hold rating count is 14 as of 9/6/2016. (NASDAQ:GILD) in a research note issued to investors on Sep-06-16, the stock received “Upgrade” rating from Hold to Buy.
In other Gilead Sciences news, CEO John F. Milligan sold 112,000 shares of Gilead Sciences stock in a transaction on Tuesday, July 5th. The institutional ownership stake in the company is 0.50% while the Beta factor stands at 1.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Following the completion of the transaction, the chairman now directly owns 4,119,727 shares of the company’s stock, valued at $349,064,468.71. The company has a market capitalization of $162.10M. Temasek Holdings Private Ltd raised its position in shares of Gilead Sciences by 8.1% in the first quarter.
During last 5 trades the stock sticks nearly -0.37%.
Over the past five trading sessions shares of Merck & Co., Inc. Finally, Riverhead Capital Management LLC raised its position in shares of Gilead Sciences by 84.2% in the first quarter. However the company’s price to cash per share for most recent quarter stands at 11.82.
Shares of Gilead Sciences (NASDAQ:GILD) opened at 77.88 on Tuesday. Gilead Sciences, Inc. P/E (price to earnings) ratio is 6.86 and Forward P/E ratio of 6.67. The stock’s current distance from 20-Day Simple Moving Average (SMA20) is -2.03% where SMA50 and SMA200 are -5.01% and -12.83% respectively.
Advertisement
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Monday, July 25th. The analysts estimated EPS for the higher end at 3.11 and lower end at 2.63 while the year ago reported earnings per share was 3.08. The firm had revenue of $7.78 billion for the quarter, compared to analyst estimates of $7.80 billion. During the same period a year ago, the company earned $3.15 EPS. (NASDAQ:GILD) has set to release EPS of $11.77 as per the sentiments of 25 analysts, however according to 25 analysts, the company expected to release $11.67 EPS for next year. The debt-to-equity ratio (D/E) was recorded at 1.42. The ex-dividend date is Wednesday, September 14th.
